戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e), IgM+/IgG+ (indeterminate), or IgM-/IgG+ (waning immunity).
2 RS-CoV-2, and that protection decreases with waning immunity.
3 26 (14%) were indeterminate, and 13 (7%) had waning immunity.
4 ut mumps vaccine effectiveness and potential waning immunity.
5 ren ages 10 to 14 years old, consistent with waning immunity.
6 d dose for outbreak control and assessed for waning immunity.
7 in highly vaccinated populations, indicating waning immunity.
8 ause of impaired initial vaccine response or waning immunity.
9 ed frequently in vaccinated individuals with waning immunity.
10 ntinues to change due to viral evolution and waning immunity.
11 hat is not universally available, as well as waning immunity.
12 ss against the delta (B.1.617.2) variant and waning immunity.
13 through infections are frequent secondary to waning immunity.
14  although ongoing surveillance for potential waning immunity after a single dose is needed.
15 ed by pockets of susceptible individuals and waning immunity after infection or vaccination, changes
16 avirus 2 (SARS-CoV-2), alongside evidence of waning immunity after the booster dose of coronavirus di
17  increasing incidence of infection is due to waning immunity after the receipt of two doses of the BN
18                               Concerns about waning immunity against severe acute respiratory syndrom
19 s, we investigate the medium-term impacts of waning immunity against severe disease on immuno-epidemi
20 eness is likely caused by, at least in part, waning immunity, although an effect of bias cannot be ru
21                                              Waning immunity among measles cases, associated with sec
22 rgences of the epidemic, we go on to include waning immunity and a mechanism explicitly accounting fo
23                                              Waning immunity and an increased incidence of coronaviru
24 vaccination coverage have been attributed to waning immunity and antigenic differences between the Je
25 ties including future behavioural change and waning immunity and assess the effectiveness of booster
26                                     However, waning immunity and breakthrough infections have been ob
27 ased vaccines have provided a way to address waning immunity and broaden protection against emerging
28 rces (instantaneous rates) of infection, but waning immunity and clinical consequences that depend on
29                               Combination of waning immunity and lower effectiveness against new SARS
30 s has been an effective strategy to overcome waning immunity and neutralization escape by emerging SA
31  pertussis resurgence has been attributed to waning immunity and other factors, vaccine refusal was s
32 een implemented in many countries to address waning immunity and reduced protection against the varia
33 that a model with either partial immunity or waning immunity and reinfection, where individuals becom
34                                              Waning immunity and the Delta variant contributed indepe
35                                    We assess waning immunity and the distribution of hybrid immunity
36 uced immunity in host populations worldwide, waning immunity and the emergence of novel variants cont
37 he remarkable efficacy of COVID-19 vaccines, waning immunity and the emergence of SARS-CoV-2 variants
38 pitalizations from SARS-CoV-2 infection, but waning immunity and the emergence of variants capable of
39 n 2022 depends largely on assumptions around waning immunity and to some extent, behaviour, and seaso
40  low vaccination rates of Influenza viruses, waning immunity and viral transmission after vaccination
41      COVID-19 booster vaccine can strengthen waning immunity and widen the range of immunity against
42 ixing, resurgent epidemic waves, patterns of waning immunity, and emerging variants that have shown s
43 ARS-CoV-2 variants, breakthrough infections, waning immunity, and sub-optimal vaccination rates accou
44 c drift phenomenologically with continuously waning immunity, and the second epochal evolution model
45 n first infections; both viral evolution and waning immunity are independently associated with reinfe
46 cine, and to evaluate age at vaccination and waning immunity as risk factors for vaccine failure.
47                These findings could indicate waning immunity but could also occur if vaccine effectiv
48 rome coronavirus 2 (SARS-CoV-2) variants and waning immunity call for next-generation vaccine strateg
49 ion behavior, new variants, vaccination, and waning immunity, can be adjusted to predict pandemic sce
50                   Onward transmission from 1 waning immunity case was documented.
51                                              Waning immunity cases had higher IgG titers than indeter
52                                  Seven (54%) waning immunity cases reported receiving measles-contain
53 ared with nonimmune and indeterminate cases, waning immunity cases were more likely to be male; less
54 te history of vaccination also suggests that waning immunity could have contributed to susceptibility
55 oupled with exposure to infected caregivers, waning immunity despite complete vaccination, inferior l
56 pact of age, pre-existing health conditions, waning immunity, different vaccination schemes and the e
57 ransmission pattern could be associated with waning immunity due to the period of very low RSV circul
58 tion and COVID-19 death protection, based on waning immunity estimates of infections and vaccination
59                                       Due to waning immunity following primary immunization with COVI
60                      Our results demonstrate waning immunity following vaccination with either Tdap b
61                                              Waning immunity from approved COVID-19 vaccines and emer
62                            In the setting of waning immunity from infection and vaccination, breakthr
63 t to which influenza recurrence depends upon waning immunity from prior infection is undefined.
64 t to which influenza recurrence depends upon waning immunity from prior-infection is undefined.
65 er, low vaccination efficacy and accelerated waning immunity have been reported in this age group.
66 ges in sustaining high vaccination coverage, waning immunity in HIV-1-infected children, and clusteri
67 genic evolution of the circulating virus and waning immunity in humans.
68  the delta (B.1.617.2) variant and potential waning immunity in observed reductions in effectiveness
69 tious Diseases held the workshop "Overcoming Waning Immunity in Pertussis Vaccines" in September 2019
70         Imported food products combined with waning immunity in some adult populations might make thi
71 ve for SARS-CoV-2, potentially counteracting waning immunity in the short term.
72   Given suboptimal global vaccination rates, waning immunity in vaccinated individuals, and the emerg
73  and 2014-2017, the proportion of cases with waning immunity increased from 0 of 87 (0%) to 13 of 103
74 any developed countries has been linked with waning immunity induced after immunization with acellula
75       In countries using acellular vaccines, waning immunity is at least part of the problem.
76                                              Waning immunity may explain the interseasonal resurgence
77 lusters of nonmedical vaccine exemptions and waning immunity may have been factors contributing to co
78 he role of nonmedical vaccine exemptions and waning immunity may have had on the resurgence of pertus
79 but inequities in vaccine administration and waning immunity may limit vaccine effectiveness.
80 ntrolling disease, but there is concern that waning immunity may predispose to reinfection.
81                                        While waning immunity may promote streptococcal epidemics, the
82                   Raising concerns about the waning immunity of cohorts receiving hepatitis B virus (
83 oncerns remain about lower effectiveness and waning immunity of rotavirus vaccines in resource-poor p
84                         With the evidence of waning immunity of the mRNA vaccine BNT162b2 (Pfizer-Bio
85                                The extent of waning immunity of the vaccine against the delta variant
86 c simulation model to evaluate the impact of waning immunity on pediatric RSV hospitalizations in the
87 nts), or decrease vaccine effectiveness (eg, waning immunity or escape variants), or increase social
88                                              Waning immunity or secondary vaccine failure (SVF) has b
89 ccine as a booster dose to address potential waning immunity over time and reduced effectiveness agai
90 rome Coronavirus 2 (SARS-CoV-2) variants and waning immunity over time require ongoing reevaluation o
91 ong vaccinated young adults, suggesting that waning immunity played a role.
92 -dose roll-out strategies, vaccine efficacy, waning immunity, population level of caution, sense of s
93 ine improved mumps outbreak control and that waning immunity probably contributed to propagation of t
94 rmation for both primary vaccine failure and waning immunity provide essential information for our pr
95                                  Analysis of waning immunity rates and oral polio vaccine transmissib
96 vaccine transmissibility reveals that higher waning immunity rates make eradication more difficult be
97 , but emerging variants of concern (VOC) and waning immunity represent significant risks at the indiv
98 Whether declines in effectiveness are due to waning immunity, the B.1.617.2 (delta) variant of the se
99                                              Waning immunity, the emergence of variants of concern, b
100 gence of SARS-CoV-2 variants and concerns of waning immunity, there is a need for better defined corr
101                                 We evaluated waning immunity to 14 pneumococcal serotypes, pertussis
102                   These results suggest that waning immunity to JEV could enhance the severity of den
103 es are necessary to understand the impact of waning immunity, viral variants and other determinants o
104                                              Waning immunity was not identified as a risk factor sinc
105 ing an age-structured vaccination model with waning immunity, we show that, under a limited supply of
106                           By considering the waning immunity, we suggest a new booster dose with BNT
107 sibility, clearance of initial infection and waning immunity were derived in a Bayesian framework by
108  model for wild poliovirus that incorporates waning immunity (which affects both infection risk and t
109 and laboratory profile of measles cases with waning immunity with other measles cases.
110 tions over time is probably primarily due to waning immunity with time rather than the delta variant
111 porating high asymptomatic ratio and rapidly waning immunity, with infection both from human and envi
112 d studies highlight the growing evidence for waning immunity within a single influenza season among v

 
Page Top